Piper Jaffray Cos. Analysts Give Collegium Pharmaceutical Inc. (COLL) a $23.00 Price Target
Collegium Pharmaceutical Inc. (NASDAQ:COLL) received a $23.00 target price from equities researchers at Piper Jaffray Cos. in a note issued to investors on Wednesday. The brokerage presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Cos.’s price target indicates a potential upside of 26.44% from the stock’s previous close.
Several other research firms have also commented on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday. Jefferies Group reissued a “buy” rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. Needham & Company LLC reissued a “buy” rating and set a $30.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Finally, Gabelli began coverage on shares of Collegium Pharmaceutical in a research report on Tuesday, September 13th. They set a “buy” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) traded down 0.302% during mid-day trading on Wednesday, hitting $18.135. 224,675 shares of the stock were exchanged. The stock has a 50-day moving average price of $13.30 and a 200 day moving average price of $14.54. The firm’s market cap is $426.68 million. Collegium Pharmaceutical has a 52-week low of $8.24 and a 52-week high of $30.58.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/piper-jaffray-cos-analysts-give-collegium-pharmaceutical-inc-coll-a-23-00-price-target.html
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.29. On average, equities research analysts expect that Collegium Pharmaceutical will post ($3.86) earnings per share for the current year.
In other Collegium Pharmaceutical news, Director John A. Fallon purchased 2,375 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The shares were bought at an average price of $10.59 per share, for a total transaction of $25,151.25. Following the acquisition, the director now owns 2,375 shares in the company, valued at $25,151.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 37.93% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,665 shares in the last quarter. Alliancebernstein L.P. bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $122,000. Royal Bank of Canada raised its stake in Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 300 shares in the last quarter. Rhumbline Advisers bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $143,000. Finally, A.R.T. Advisors LLC bought a new stake in Collegium Pharmaceutical during the second quarter valued at approximately $148,000. Institutional investors and hedge funds own 62.13% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.